Thank you for joining us. The program will commence momentarily. - PowerPoint PPT Presentation

Thank you for joining us. The program will commence momentarily.

Optimizing the Selection and Sequencing of Therapy for Patients with Chronic Lymphocytic Leukemia A Meet The Professor Series Ian W Flinn, MD, PhD Director of Lymphoma Research Program Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee

Commercial Support These activities are supported by educational grants from AbbVie Inc and AstraZeneca Pharmaceuticals LP.

Dr Love — Disclosures Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Dr Flinn — Disclosures AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Gilead Sciences Inc, Great Point Partners LLC, Iksuda Therapeutics, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, MorphoSys, Nurix Therapeutics Inc, Pharmacyclics Consulting Agreements LLC, an AbbVie Company, Roche Laboratories Inc, ScienceCurio, Seattle Genetics, Takeda Oncology, Unum Therapeutics, Verastem Inc, Vincere Biosciences Inc, YL-Pharma Co Ltd AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Agios Pharmaceuticals Inc, ArQule Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Calithera Biosciences, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, F Hoffmann-La Roche Ltd, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, IGM Biosciences Inc, Incyte Contracted Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, Research a Celgene Company, Karyopharm Therapeutics, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MorphoSys, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, Rhizen Pharmaceuticals SA, Roche Laboratories Inc, Seattle Genetics, Takeda Oncology, Teva Oncology, TG Therapeutics Inc, Trillium Therapeutics Inc, Triphase Research & Development Corp, Unum Therapeutics, Verastem Inc

We Encourage Clinicians in Practice to Submit Questions Feel free to submit questions now before the program commences and throughout the program.

Familiarizing Yourself with the Zoom Interface How to answer poll questions When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.

Upcoming Live Webinars Wednesday, September 16, 2020 Friday, September 18, 2020 12:00 PM – 1:00 PM ET 12:00 PM – 1:00 PM ET Clinical Investigator Optimizing the Selection and Perspectives on the Current Sequencing of Therapy for and Future Management of Patients with Chronic Multiple Myeloma Lymphocytic Leukemia Faculty Faculty Jonathan L Kaufman, MD Matthew S Davids, MD, MMSc Moderator Moderator Neil Love, MD Neil Love, MD

Thank you for joining us! CME and MOC credit information will be emailed to each participant within 5 days.

Optimizing the Selection and Sequencing of Therapy for Patients with Chronic Lymphocytic Leukemia A Meet The Professor Series Ian W Flinn, MD, PhD Director of Lymphoma Research Program Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee

Meet The Professor Program Participating Faculty Matthew S Davids, MD, MMSc Brian T Hill, MD, PhD Associate Professor of Medicine Director, Lymphoid Malignancy Program Harvard Medical School Cleveland Clinic Taussig Cancer Institute Director of Clinical Research Cleveland, Ohio Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Ian W Flinn, MD, PhD Brad S Kahl, MD Director of Lymphoma Research Program Professor of Medicine Sarah Cannon Research Institute Washington University School of Medicine Tennessee Oncology Director, Lymphoma Program Nashville, Tennessee Siteman Cancer Center St Louis, Missouri

Meet The Professor Program Participating Faculty Anthony R Mato, MD, MSCE Kerry Rogers, MD Associate Attending Assistant Professor in the Division of Hematology Director, Chronic Lymphocytic Leukemia The Ohio State University Program Columbus, Ohio Memorial Sloan Kettering Cancer Center New York, New York John M Pagel, MD, PhD Jeff Sharman, MD Chief of Hematologic Malignancies Willamette Valley Cancer Institute and Center for Blood Disorders and Stem Research Center Cell Transplantation Medical Director of Hematology Research Swedish Cancer Institute US Oncology Seattle, Washington Eugene, Oregon

Meet The Professor Program Participating Faculty Mitchell R Smith, MD, PhD Jennifer Woyach, MD Professor of Medicine Professor Associate Center Director for Clinical Division of Hematology Investigations Department of Internal Medicine Director, Division of Hematology and Oncology The Ohio State University GW Cancer Center Comprehensive Cancer Center Washington, DC Columbus, Ohio Project Chair William G Wierda, MD, PhD Neil Love, MD DB Lane Cancer Research Research To Practice Distinguished Professor Miami, Florida Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, Texas

We Encourage Clinicians in Practice to Submit Questions You may submit questions using the Zoom Chat option below Feel free to submit questions now before the program commences and throughout the program.

Familiarizing Yourself with the Zoom Interface How to answer poll questions When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.

Clinical Investigator Perspectives on the Current and Future Management of Multiple Myeloma A Meet The Professor Series Wednesday, September 16, 2020 12:00 PM – 1:00 PM ET Faculty Jonathan L Kaufman, MD Moderator Neil Love, MD Co-provided by

Optimizing the Selection and Sequencing of Therapy for Patients with Chronic Lymphocytic Leukemia A Meet The Professor Series Friday, September 18, 2020 12:00 PM – 1:00 PM ET Faculty Matthew S Davids, MD, MMSc Moderator Neil Love, MD

Optimizing the Selection and Sequencing of Therapy for Patients with Chronic Lymphocytic Leukemia A Meet The Professor Series Ian W Flinn, MD, PhD Director of Lymphoma Research Program Sarah Cannon Research Institute Tennessee Oncology Nashville, Tennessee

Ranju Gupta, MD Attending Physician Co-Director, Cardio-Oncology program LVPG Hematology Oncology Associates Lehigh Valley Health Network Bethlehem, Pennsylvania

Meet The Professor with Dr Flinn MODULE 1: Cases from the Community – Dr Gupta • A 79-year-old man with relapsed CLL – Part 1 • A 79-year-old man with relapsed CLL – Part 2 • A 79-year-old man with relapsed CLL – Part 3 • A 55-year-old man with relapsed CLL • A fit 75-year-old man with relapsed CLL – Part 1 • A fit 75-year-old man with relapsed CLL – Part 2 MODULE 2: Beyond the Guidelines – Clinical Investigator Approaches to Common Clinical Scenarios MODULE 3: Key Recent Data Sets • PFS and rate and duration of MRD negativity with venetoclax/obinutuzumab (CLL14 trial) • FDA approval of acalabrutinib (ELEVATE-TN trial) • Ibrutinib/rituximab in older (Alliance A041202 trial) and younger (ECOG-E1912 trial) patients • CAPTIVATE MRD cohort • Available data and current clinical role of ibrutinib/obinutuzumab (iLLUMINATE trial) • Venetoclax/rituximab (MURANO trial) • Acalabrutinib (ASCEND trial) • Side effects associated with BTK inhibitors and venetoclax-associated toxicities